Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 5Completed 3Terminated 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Biliary Tract Neoplasms 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × telotristat ethyl × Clear all
NCT04543955 2023-06-27

Telotristat With Lutathera in Neuroendocrine Tumors

University of Kentucky

Phase 2 Terminated
1 enrolled 4 charts
EndocrineNET

Neuroendocrine Tumors

NCT03790111 2023-04-19

TELE-ABC

TerSera Therapeutics LLC

Phase 2 Terminated
53 enrolled 47 charts
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡